Should I buy or sell Onconova Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks .

What is Onconova Therapeutics' stock price target for 2024?

1 equities research analysts have issued twelve-month price objectives for Onconova Therapeutics' shares. Their ONTX share price targets range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts .

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 26,200 shares, an increase of 26.6% from the March 15th total of 20,700 shares. Based on an average daily trading volume, of 41,700 shares, the short-interest ratio is currently 0.6 days. View Onconova Therapeutics' Short Interest .

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ONTX earnings forecast .

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. During the same period in the previous year, the business earned ($0.45) EPS.

When did Onconova Therapeutics' stock split?

Onconova Therapeutics's stock reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Tonix Pharmaceuticals (TNXP) , Acasti Pharma (ACST) , Bionano Genomics (BNGO) , Matinas BioPharma (MTNB) , Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM) .

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ONTX

Onconova Therapeutics (ONTX) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free ONTX Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $0.67
▼
$1.01
52-Week Range: N/A

Volume: 1.28 million shs
Average Volume: 96,681 shs
Market Capitalization: $20.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get Onconova Therapeutics alerts:

Onconova Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: ∞ Upside
$11.00 Price Target
Short Interest: Healthy
0.12% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.72) to ($0.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.26 out of 5 stars

Medical Sector

684th out of 928 stocks

Pharmaceutical Preparations Industry

316th out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
Onconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Onconova Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.12% of the outstanding shares of Onconova Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Onconova Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Onconova Therapeutics has recently increased by 26.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Onconova Therapeutics does not currently pay a dividend.
Dividend Growth
Onconova Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONTX.

2.4

News and Social Media Coverage

News Sentiment
Onconova Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Onconova Therapeutics this week, compared to 1 article on an average week.
Search Interest
7 people have searched for ONTX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.30% of the stock of Onconova Therapeutics is held by insiders.
Percentage Held by Institutions
Only 7.95% of the stock of Onconova Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Onconova Therapeutics are expected to decrease in the coming year, from ($0.72) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Onconova Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Onconova Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Onconova Therapeutics Stock (NASDAQ:ONTX)

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

ONTX Stock News Headlines

April 16, 2024 | americanbankingnews.com

Onconova Therapeutics (NASDAQ:ONTX) Coverage Initiated at StockNews.com

April 8, 2024 | americanbankingnews.com

Onconova Therapeutics (NASDAQ:ONTX) Now Covered by Analysts at StockNews.com

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

April 4, 2024 | uk.investing.com

Onconova and Trawsfynydd merge to form Traws Pharma

April 4, 2024 | finance.yahoo.com

Traws Pharma Full Year 2023 Earnings: Beats Expectations

April 3, 2024 | msn.com

Newtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with Trawsfynydd

April 2, 2024 | markets.businessinsider.com

Onconova Acquires Trawsfynydd To Form Traws Pharma

April 2, 2024 | globenewswire.com

Traws Pharma Announces New Employee Inducement Grants

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 12, 2024 | msn.com

Onconova to Unveil New Rigosertib Study Results at Cancer Research Meeting

March 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)

March 8, 2024 | finance.yahoo.com

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

March 8, 2024 | globenewswire.com

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

February 13, 2024 | investing.com

Onconova Therapeutics Inc (ONTX)

January 23, 2024 | finance.yahoo.com

Onconova Therapeutics, Inc. (ONTX)

December 21, 2023 | benzinga.com

Onconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and Dates

December 12, 2023 | msn.com

Onconova stock falls 10% on preclinical data for lymphoma drug

December 12, 2023 | finance.yahoo.com

Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

December 8, 2023 | finance.yahoo.com

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

November 28, 2023 | finance.yahoo.com

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

November 16, 2023 | finance.yahoo.com

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcript

November 16, 2023 | finanznachrichten.de

Onconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

November 14, 2023 | finance.yahoo.com

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

November 7, 2023 | finance.yahoo.com

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

November 2, 2023 | benzinga.com

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

November 2, 2023 | finance.yahoo.com

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

October 19, 2023 | markets.businessinsider.com

Promising Developments in Onconova Therapeutics’ Drug Narazaciclib Bolster Buy Rating: An Analysis

See More Headlines

Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2021
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ONTX
CUSIP: N/A
CIK: 1130598
Web: www.onconova.com
Phone: (267) 759-3680
Fax: 267-759-3681
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,960,000.00
Net Margins: -8,930.97%
Pretax Margin: -8,930.97%
Return on Equity: -95.43%
Return on Assets: -61.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.79
Quick Ratio: 2.79

Sales & Book Value

Annual Sales: $230,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.35 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 21,000,000
Free Float: 20,310,000
Market Cap: $20.90 million
Optionable: Optionable
Beta: 1.38

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Steven M. Fruchtman M.D. (Age 73)
CEO, President & Director
Comp: $907.86k
Mr. Mark Patrick Guerin CPA (Age 55)
CFO & COO
Comp: $629.27k
Dr. Victor Moyo M.D.
Chief Medical Officer

Key Competitors

View All Competitors

ONTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings or view top-rated stocks.
What is Onconova Therapeutics' stock price target for 2024?: 1 equities research analysts have issued twelve-month price objectives for Onconova Therapeutics' shares. Their ONTX share price targets range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months.
View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts.
Are investors shorting Onconova Therapeutics?: Onconova Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 26,200 shares, an increase of 26.6% from the March 15th total of 20,700 shares. Based on an average daily trading volume, of 41,700 shares, the short-interest ratio is currently 0.6 days.
View Onconova Therapeutics' Short Interest.
When is Onconova Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ONTX earnings forecast.

How were Onconova Therapeutics' earnings last quarter?: Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. During the same period in the previous year, the business earned ($0.45) EPS.
When did Onconova Therapeutics' stock split?: Onconova Therapeutics's stock reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Onconova Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).
How do I buy shares of Onconova Therapeutics?: Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Onconova Therapeutics (ONTX) Stock Price, News & Analysis

Onconova Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Onconova Therapeutics Stock (NASDAQ:ONTX)

ONTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ONTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™